<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Radiol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Radiol</journal-id><journal-id journal-id-type="pmc-domain-id">1897</journal-id><journal-id journal-id-type="pmc-domain">brjradiol</journal-id><journal-id journal-id-type="publisher-id">bjr</journal-id><journal-title-group><journal-title>The British Journal of Radiology</journal-title></journal-title-group><issn pub-type="ppub">0007-1285</issn><issn pub-type="epub">1748-880X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10646649</article-id><article-id pub-id-type="pmcid-ver">PMC10646649.1</article-id><article-id pub-id-type="pmcaid">10646649</article-id><article-id pub-id-type="pmcaiid">10646649</article-id><article-id pub-id-type="pmid">37751214</article-id><article-id pub-id-type="doi">10.1259/bjr.20220763</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Full Paper</subject></subj-group><subj-group subj-group-type="topic"><compound-subject><compound-subject-part content-type="code">bjr</compound-subject-part><compound-subject-part content-type="label">BJR</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">rt-onc</compound-subject-part><compound-subject-part content-type="label">Radiotherapy and Oncology</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery</article-title><alt-title alt-title-type="right-running-head">Effects of Driver Mutations on Pathologic Response in NSCLC</alt-title><alt-title alt-title-type="left-running-head">Appel <italic toggle="yes">et al</italic></alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Appel</surname><given-names initials="S">Sarit</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:sarit.appel@sheba.health.gov.il">sarit.appel@sheba.health.gov.il</email><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:saritappel8@gmail.com">saritappel8@gmail.com</email></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bar</surname><given-names initials="J">Jair</given-names></name><degrees>MD</degrees><xref rid="aff2 aff3" ref-type="aff">2,3</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Jair.Bar@sheba.health.gov.il">Jair.Bar@sheba.health.gov.il</email><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bar.jair@gmail.com">bar.jair@gmail.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saad</surname><given-names initials="A">Akram</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">2</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Akram.Saad@sheba.health.gov.il">Akram.Saad@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marom</surname><given-names initials="EM">Edith Michelle</given-names></name><degrees>MD</degrees><xref rid="aff3 aff4" ref-type="aff">3,4</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Edith.Marom@sheba.health.gov.il">Edith.Marom@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Urban</surname><given-names initials="D">Damien</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">2</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Damien.Urban@sheba.health.gov.il">Damien.Urban@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onn</surname><given-names initials="A">Amir</given-names></name><degrees>MD</degrees><xref rid="aff2 aff3" ref-type="aff">2,3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gantz-Sorotsky</surname><given-names initials="H">Hadas</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">2</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Hadas.GantzSorotsky@sheba.health.gov.il">Hadas.GantzSorotsky@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kremer</surname><given-names initials="RY">Ran Yosef</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">5</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Ran.Kremer@sheba.health.gov.il">Ran.Kremer@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ben-Nun</surname><given-names initials="A">Alon</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">6</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:alonbe@assuta.co.il">alonbe@assuta.co.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perelman</surname><given-names initials="M">Marina</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">7</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Marina.Perelman@sheba.health.gov.il">Marina.Perelman@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ofek</surname><given-names initials="E">Efrat</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">7</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Efrat.Ofek@sheba.health.gov.il">Efrat.Ofek@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yacobi</surname><given-names initials="R">Rinat</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">7</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Rinat.Yacobi@sheba.health.gov.il">Rinat.Yacobi@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daher</surname><given-names initials="S">Sameh</given-names></name><degrees>MD</degrees><xref rid="aff8" ref-type="aff">8</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:S_Daher@rambam.health.gov.il">S_Daher@rambam.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rasco</surname><given-names initials="A">Adi</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">9</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:rascoa@shamir.gov.il">rascoa@shamir.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Symon</surname><given-names initials="Z">Zvi</given-names></name><degrees>MD</degrees><xref rid="aff1 aff3" ref-type="aff">1,3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lawrence</surname><given-names initials="YR">Yaacov Richard</given-names></name><degrees>MD</degrees><xref rid="aff1 aff3" ref-type="aff">1,3</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Yaacov.Lawrence@sheba.health.gov.il">Yaacov.Lawrence@sheba.health.gov.il</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goldstein</surname><given-names initials="J">Jeffrey</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">10</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:jgoldstein5555@gmail.com">jgoldstein5555@gmail.com</email></contrib><aff id="aff1">
<label>1</label>
<institution content-type="org-division">Department of Radiation Oncology, Chaim Sheba Medical Center</institution>, <addr-line>Tel- Hashomer</addr-line>, <country>Israel</country>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="org-division">Department of Medical Oncology, Chaim Sheba Medical Center</institution>, <addr-line>Tel-Hashomer</addr-line>, <country>Israel</country>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="org-division">Tel Aviv University the Sackler Faculty of Medicine</institution>, <addr-line>Tel Aviv</addr-line>, <country>Israel</country>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="org-division">Department of Radiology, Chaim Sheba Medical Center</institution>, <addr-line>Tel-Hashomer</addr-line>, <country>Israel</country>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="org-division">Department of Thoracic Surgery, Chaim Sheba Medical Center</institution>, <addr-line>Tel-Hashomer</addr-line>, <country>Israel</country>
</aff><aff id="aff6">
<label>6</label>
<institution content-type="org-division">Department of Thoracic Surgery, Assuta Medical Center</institution>, <addr-line>Tel Aviv</addr-line>, <country>Israel</country>
</aff><aff id="aff7">
<label>7</label>
<institution content-type="org-division">Department of Pathology, Chaim Sheba Medical Center</institution>, <addr-line>Tel-Hashomer</addr-line>, <country>Israel</country>
</aff><aff id="aff8">
<label>8</label>
<institution content-type="org-division">Thoracic Cancer Unit Cancer Division, Rambam Health Care Campus</institution>, <addr-line>Haifa</addr-line>, <country>Israel</country>
</aff><aff id="aff9">
<label>9</label>
<institution content-type="org-division">Department of Medical Oncology, Kaplan Medical Center</institution>, <addr-line>Rehovot</addr-line>, <country>Israel</country>
</aff><aff id="aff10">
<label>10</label>
<institution content-type="org-division">Department of Radiation Oncology, Tel-Aviv Medical Center</institution>, <addr-line>Tel-Aviv</addr-line>, <country>Israel</country>
</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to: Dr Sarit Appel. E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:sarit.appel@sheba.health.gov.il">sarit.appel@sheba.health.gov.il</email><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:saritappel8@gmail.com">saritappel8@gmail.com</email></corresp><corresp id="cor2">Address correspondence to: Prof Jair Bar. E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Jair.Bar@sheba.health.gov.il">Jair.Bar@sheba.health.gov.il</email><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bar.jair@gmail.com">bar.jair@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2023</year></pub-date><volume>96</volume><issue>1152</issue><issue-id pub-id-type="pmc-issue-id">449161</issue-id><elocation-id>20220763</elocation-id><history><date date-type="received"><day>06</day><month>8</month><year>2022</year></date><date date-type="rev-recd"><day>26</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>24</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-27 15:25:13.833"><day>27</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Authors. Published by the British Institute of Radiology</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bjr.20220763.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="bjr.20220763.pdf"/><abstract><sec><title>Objective</title><p>We hypothesized that driver mutations in epidermal growth factor receptor (EGFR) are associated with decreased pathologic response to neoadjuvant chemoradiation (NA-ChRT) in locally advanced non-small cell lung cancer (LA-NSCLC).</p></sec><sec><title>Methods</title><p>Patients with Stage IIB-IIIA NSCLC treated with NA-ChRT, completion surgery, and underwent molecular profile testing were identified in a lung cancer database. Pathologic response was quantified using: (i) major pathologic response (MPR), (ii) complete pathologic response (pCR), and (iii) mean residual viable tumor cells (MRTC). Two groups were formed based on the presence or absence of driver mutations. Clinical and pathological correlations between the groups were studied.</p></sec><sec><title>Results</title><p>Forty-seven patients underwent tumor molecular profile testing, NA-ChRT, and completion surgery. Compared to the no-driver mutation group, the driver mutation group had lower MPR (23% <italic toggle="yes">vs</italic> 71%, <italic toggle="yes">p</italic> = 0.003), pCR (0% <italic toggle="yes">vs</italic> 26%, <italic toggle="yes">p</italic> = 0.02), and higher MRTC (43.4% <italic toggle="yes">vs</italic> 15.8%, <italic toggle="yes">p</italic> = 0.009). Univariate analysis showed an increased MPR rate for smokers, squamous cell histology, ChRT-surgery interval &gt;65 days, and no-driver mutations. Multivariate analysis showed that only no-driver mutations (OR 0.39, <italic toggle="yes">p</italic> = 0.02) remained significant for MPR. PD-L1 status did not affect MPR. At 2 years, the driver mutation group had lower rates of local control (Hazard ration [HR] 0.67, <italic toggle="yes">p</italic> = 0.17) and disease-free survival (HR 0.5, <italic toggle="yes">p</italic> = 0.001). Overall survival was similar for both groups (HR = 1.04, <italic toggle="yes">p</italic> = 0.86).</p></sec><sec><title>Conclusion</title><p>Following 60 Gray NA-ChRT, tumors with a driver mutation had lower MPR and pCR rates than tumors without a driver mutation. PD-L1 was not associated with tumor regression.</p></sec><sec><title>Advances in knowledge</title><p>Patients with resectable LA-NSCLC and an EGFR driver mutation treated with neoadjuvant-ChRT and completion surgery have reduced pathologic regression, lower local control rates, and shorter disease-free survival than patients without a driver mutation. Evaluation of molecular testing should be introduced in LA-NSCLC intended for prognostication and treatment decisions.</p></sec></abstract><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="44"/><page-count count="11"/><word-count count="7397"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Epidermal growth factor receptor (EGFR/ErbB1) driver mutations are valuable biomarkers for predicting response to tyrosine kinase inhibitors (TKIs) in patients with metastatic lung adenocarcinoma.<sup>
<xref rid="b1" ref-type="bibr">1,2</xref>
</sup> There is indirect evidence suggesting that the presence of EGFR/ErbB1 driver mutations may also offer prognostic information for patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with chemoradiation (ChRT).<sup>
<xref rid="b3" ref-type="bibr">3</xref>
</sup> Evaluating the effects of TKIs in patients with LA-NSCLC treated with ChRT alone has been limited since molecular profiling of the tumor prior to starting treatment has not been mandatory.<sup>
<xref rid="b4" ref-type="bibr">4,5</xref>
</sup> A recent analysis of the PACIFIC trial showed that patients with unresectable LA-NSCLC treated with adjuvant durvalumab following ChRT had improved disease-free survival (DFS) and overall survival (OS), suggested that patients with EGFR mutations may benefit less from treatment with adjuvant durvalumab than patients without EGFR mutations.<sup>
<xref rid="b6" ref-type="bibr">6</xref>
</sup> However, since EGFR mutations were present in only 6% of patients enrolled in this trial, these results should be interpreted cautiously. Currently, most patients with unresectable LA-NSCLC are treated with definitive ChRT followed by adjuvant durvalumab without first testing for the presence of driver mutations.<sup>
<xref rid="b4" ref-type="bibr">4&#8211;7</xref>
</sup>
</p><p>Since patients with driver mutations may benefit from including targeted therapies into their therapeutic regime, there is growing interest in extending TKIs to patients with LA-NSCLC who harbor EGFR mutations. Prior studies investigating adjuvant cetuximab or erlotinib/gefitinib failed to improve OS in patients with LA-NSCLC and driver mutations.<sup>
<xref rid="b8" ref-type="bibr">8&#8211;10</xref>
</sup> More recently, the phase III ADAURA trial showed the use of adjuvant osimertinib for 3 years in patients with completely resected, EGFR mutated, Stage IB-IIIA NSCLC was associated with improved DFS compared to treatment with placebo (90% <italic toggle="yes">vs</italic> 44%, <italic toggle="yes">p</italic> &lt; 0.001). Despite the use of adjuvant platinum-based chemotherapy (ChT) in 26% of patients with Stage IB disease and 76% of patients with Stage II-IIIA disease in addition to osimertinib, the improvement in DFS associated with the use of osimertinib compels further investigation with targeted therapies.<sup>
<xref rid="b11" ref-type="bibr">11,12</xref>
</sup> Currently, to improve outcomes in patients with EGFR mutations, the phase III NEOADUARA trial is evaluating the use of neoadjuvant osimertinib in addition to adjuvant osimertinib in patients with resectable NSCLC,<sup>
<xref rid="b13" ref-type="bibr">13</xref>
</sup> and the phase III LAURA trial is enrolling patients with Stage III unresectable LA-NSCLC to evaluate the use of osimertinib following completion of definitive ChRT.<sup>
<xref rid="b14" ref-type="bibr">14</xref>
</sup>
</p><p>Zens et al<sup>
<xref rid="b15" ref-type="bibr">15</xref>
</sup> and other authors suggested that the amount of pathologic regression in surgical specimens following NA-ChT or NA-ChRT in LA-NSCLC is an important prognostic factor associated with improved DFS and OS.<sup>
<xref rid="b16" ref-type="bibr">16&#8211;19</xref>
</sup> Pataer et al showed in 192 NSCLC patients who received NA-ChT followed by surgery that both surgical pathologic stage and the presence of a major pathologic regression (MPR, &#8804;10% viable tumor cells) were associated with improved OS and DFS. Other authors concluded the same, making MPR a strong prognosticator for OS and DFS in patients with NSCLC.<sup>
<xref rid="b20" ref-type="bibr">20&#8211;22</xref>
</sup> We hypothesized that driver mutations are associated with reduced tumor regression in surgical specimens following NA-ChRT.</p><p>To evaluate the effect of driver mutations on pathologic regression, we utilized a unique cohort of patients with resectable LA-NSCLC treated according to our institutional protocol with NA-ChRT followed by completion surgery (references blinded). Our primary end point was pathologic regression. Secondary end points were local control (LC), DFS, and OS. We correlated both primary and secondary end points to the presence or absence of EGFR mutations, PD-L1 status, and rare mutations.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Patients</title><p>We conducted a retrospective analysis of a database to identify patients with resectable Stage IIB-III NSCLC treated with NA-ChRT followed by pre-planned completion surgery that underwent tumor molecular profile testing at Sheba Medical Center between 2012 and 2021. Exclusion criteria for this analysis were unresectable disease, local or distant progression of disease during or after completion of ChRT, absence of molecular profile testing, radiation dose &lt;50 Gy or &#8805;72 Gray (Gy), or non-concurrent ChRT. We excluded patients who underwent salvage surgery for progressive disease from this analysis.</p><p>Variables collected included age, sex, smoking history (current, past-smoker, never-smoker), clinical stage, gross tumor volume (GTV), lymph node volume, histology (adenocarcinoma, squamous cell carcinoma, and other histology), and tumor location (upper, middle, or lower lobes). We defined total tumor volume as the combined GTV and lymph node volumes. Treatment variables collected were the type of NA-ChT administered, radiation dose, radiation technique, use of adaptive replanning during the treatment course, use of durvalumab prior to surgery, the time interval between completion of NA-ChRT and surgery, and type of surgical procedure.</p></sec><sec id="s2-2"><title>Molecular testing</title><p>We performed molecular testing to identify genetic alterations in tumor DNA; on the primary tumor or lymph nodes before starting ChRT, on lesions resected after ChRT and surgery, or on metastatic lesions. Kits used to determine the biomarkers changed during the time frame of this study, and based on the change in the standard testing used during different periods included EGFR testing using INFINITI<sup>&#8482;</sup> Analyze (Auto Genomics, Carlsbad, CA)<sup>
<xref rid="b23" ref-type="bibr">23</xref>
</sup> till 2018. After March 2018, Oncomine (Thermo Fisher Scientific, Waltham, MA), a next-generation sequencing test kit that analyzes for the presence of 22 genes simultaneously, was used to test for EGFR, ALK, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, MET, DDR2, KRAS, PIK3CA, BRAF, AKT1, PTEN, NRAS, MAP2K1, STK11, NOTCH1, CTNNB1, SMAD4, FBXW7 and TP53.<sup>
<xref rid="b24" ref-type="bibr">24,25</xref>
</sup> Cases were assigned and analyzed according to the dominant genetic alteration, defined as the genetic alteration with the highest percentage of expression when several genetic alterations were detected.</p><p>PD-L1 expression was tested on archived tumor samples and measured by immunohistochemistry (Ventana Medical Systems, Oro Valley, AZ). The percentage of PD-L1 immunohistochemistry (IHC) staining was recorded from the pathologic specimens either before or after NA-ChRT and graded into three groups; negative (&lt;1% positive staining), weakly positive (1&#8211;49%), and strongly positive (&#8805;50%).<sup>
<xref rid="b26" ref-type="bibr">26</xref>
</sup>
</p></sec><sec id="s2-3"><title>Treatment</title><p>Since 2012, the practice at Sheba Medical Center for resectable LA-NSCLC was to deliver NA-ChRT using platinum-based doublet ChT concomitantly with RT to a dose of 60 Gray (Gy), followed by restaging and then completion surgery for cases without local or distant progression. The NA-ChRT and surgical treatment protocols utilized at our center have been reported previously.<sup>
<xref rid="b27" ref-type="bibr">27</xref>
</sup> Since 2016, RT delivery protocol used volumetric arc therapy (VMAT, Varian Inc. Palo Alto, CA), with daily image-guided radiation therapy (IGRT) using cone beam computerized tomography (CBCT). As shown previously, using VMAT or three-dimensional conformal radiation therapy (3DCRT) planning resulted in similar rates of pathologic regression,<sup>
<xref rid="b28" ref-type="bibr">28</xref>
</sup> thus both techniques were included.</p><p>Since the introduction of durvalumab, patients with borderline resectable stage-III disease, whose extent of disease was initially considered borderline for surgery, were offered the option of receiving adjuvant durvalumab. After repeated CT imaging and reevaluation, the multidisciplinary team decided to discontinue the durvalumab and proceed with completion surgery.</p></sec><sec id="s2-4"><title>Pathologic response</title><p>Pathologic response to NA-ChRT was assessed from surgical specimens and quantified using three measures of pathologic response: (i) major pathologic response (MPR &#8804;10% viable tumor cells) <italic toggle="yes">vs</italic> no MPR (&gt;10% tumor viable tumor cells), (ii) complete pathologic responses (pCR) and (iii) the percentage of mean residual viable tumor cells (MRTC). The pathologists interpreting the specimens were unaware of the presence or absence of driver mutations. <xref rid="F1" ref-type="fig">Figure 1</xref> shows examples of treatment effects: pCR, MPR, and residual disease.</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>(a<bold>&#8211;</bold>c): Example pathology slides of lobectomies after chemoradiation showing treatment effect: (a) pCR pathologic compleate response, (b) MPR major pathologic regression and (c) Residual disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bjr.20220763.g001.jpg"/></fig></sec><sec id="s2-5"><title>Follow-up and clinical outcome</title><p>Patient follow-up examinations and imaging studies with CT or fludeoxyglucose (FDG) positron emission tomography (PET)-CT were done based on the standard of care, usually at 3 month intervals in the first-year post-surgery and then at 4&#8211;6 month intervals or as clinically indicated. We recorded the first recurrence as a local, regional, or distant failure.</p></sec><sec id="s2-6"><title>Statistical analysis</title><p>Descriptive statistics used to assess patient and treatment parameters included proportions, means, and standard deviations. We compared variables between groups using a &#967;<sup>2</sup> test, unpaired <italic toggle="yes">t</italic>-test (for age), Wilcoxon rank-sum (Mann&#8211;Whitney) test, Kruskal&#8211;Wallis for continuous variables not normally distributed, and Spearman&#8217;s rank test to correlate MRTC with continuous variables. We conducted univariate and multivariate logistic regression to predict the odds ratio (OR) for MPR. Patients were sorted into groups based on the presence or absence of driver mutations and subdivided based on surgical specimens&#8217; pathologic response. We excluded rare mutations represented by only a single case from the regression models. Multivariate analysis (MVA) models included variables with a <italic toggle="yes">p</italic>-value of &lt; 0.2 in the univariate analysis (UVA). We excluded variables correlating with EGFR with significant (<italic toggle="yes">p</italic> &#8804; 0.05) correlation coefficients from the MVA. OS was recorded from the start of NA-ChRT till death or censured at the last time the patient was known to be alive. Local and distant progression were recorded from patients' medical records or review of CT or FDG PET-CT imaging studies and was calculated from the initiation of NA-ChRT till progression or censure at the last evaluation. Time-to-event data were analyzed using the Kaplan&#8211;Meier method. We excluded driver mutations represented by a single case from the Kaplan&#8211;Meier analysis. We used hazard ratios (HRs) to compare local failure, distant failure, and survival rates. A <italic toggle="yes">p</italic>-value &#8804; 0.05 was considered statistically significant. We used STATA v. 13 (StataCorp. 2013, Stata Statistical Software: Release 13. College Station, TX: StataCorp LP) for all statistical analysis.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>During the study period, 107 patients with resectable LA-NSCLC were treated with NA-ChRT followed by surgery. Tumor molecular profile testing was available in 47 patients. Patients not undergoing testing for mutations (<italic toggle="yes">n</italic> = 60) were excluded from this analysis.</p><p>The patient characteristics, shown in <xref rid="T1" ref-type="table">Table 1</xref>, are subdivided into two groups based on tumor molecular profile testing results. The driver mutation group included patients with alterations in recognized drivers; EGFR (<italic toggle="yes">n</italic> = 13), BRAF (<italic toggle="yes">n</italic> = 1), RET (<italic toggle="yes">n</italic> = 1), and ROS1 (<italic toggle="yes">n</italic> = 1). The no-driver mutation group included all patients with no mutation identified (<italic toggle="yes">n</italic> = 17) as well as patients with mutation or aberration in FGFR (<italic toggle="yes">n</italic> = 2), KRAS (<italic toggle="yes">n</italic> = 10), ERBB4 (<italic toggle="yes">n</italic> = 1), or AKT (<italic toggle="yes">n</italic> = 1). Although some of these genes may be considered driver mutations, we designated this group the &#8216;no-driver-mutation group&#8217; since, besides KRAS, none were proven drivers in lung cancer. Patients with KRAS mutation have clinical characteristics similar to patients with no-driver mutations, justifying their inclusion within the &#8216;no-driver mutation&#8217; group.<sup>
<xref rid="b29" ref-type="bibr">29</xref>
</sup>
</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Patient characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">All patients</th><th align="center" valign="bottom" rowspan="1" colspan="1">No-driver mutation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Driver mutation</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p-</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient number</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (8.9)</td><td align="center" valign="top" rowspan="1" colspan="1">62 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">59 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Female</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Male</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Never</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Past</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Current</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Histology:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Squamous cell carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Other</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stage (AJCC 7th ed.):</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;II</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;III</td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;IV</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor location:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Upper /middle lobes</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Lower lobes</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemotherapy:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cisplatin-vinorelbine</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Carboplatin-paclitaxel</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Platinum-etoposide</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cisplatin-pemetrexed</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neoadjuvant durvalumab:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;No</td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Surgery type:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Chest wall resection + lobectomy</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Lobectomy</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Pneumonectomy</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PDL1 IHC (total 34) percent (mean, (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">29.1(33)</td><td align="center" valign="top" rowspan="1" colspan="1">29.4 (35)</td><td align="center" valign="top" rowspan="1" colspan="1">28.7 (30.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weak positive (&lt;50%)</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Strong positive (&#8805;50%)</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiation dose: (Mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">61.2 (5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Planning technique:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;three-dimensional fields (3DCRT)</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Volumetric arc (VMAT)</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adaptive volumetric: replanning</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;No</td><td align="center" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Missing</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total GTV volume primary + nodes (cm<sup>3</sup>), (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">140 (119)</td><td align="center" valign="top" rowspan="1" colspan="1">172 (132)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (54.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GTV, cm<sup>3</sup>, (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">110 (123)</td><td align="center" valign="top" rowspan="1" colspan="1">143 (137)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (47.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymph nodes volume, cm<sup>3</sup> (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">30.7 (32.6)</td><td align="center" valign="top" rowspan="1" colspan="1">29.6 (37)</td><td align="center" valign="top" rowspan="1" colspan="1">32.6 (22)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lung V20 (%) (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">23.1 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">23.4 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean lung dose (Gy) (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">13.6 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">13.6 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">13.6 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lung V5 (%) (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">48.3 (14.6)</td><td align="center" valign="top" rowspan="1" colspan="1">48.4 (16)</td><td align="center" valign="top" rowspan="1" colspan="1">48.3 (11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart V45 (%) (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5 (11.8)</td><td align="center" valign="top" rowspan="1" colspan="1">7.9 (13.4)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (11.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean heart dose (Gy) (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (9.2)</td><td align="center" valign="top" rowspan="1" colspan="1">9.65 (9.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (8.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spine max dose (Gy) (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">38.3 (11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">37.5 (13.2)</td><td align="center" valign="top" rowspan="1" colspan="1">29.8 (8.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PTV D95% (mean, SD)</td><td align="center" valign="top" rowspan="1" colspan="1">95.5 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">95 (2.7)</td><td align="center" valign="top" rowspan="1" colspan="1">96.4 (3.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interval between radiation and surgery (days) (mean, SD) (including durvalumab)</td><td align="center" valign="top" rowspan="1" colspan="1">72.8 (44.7)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (50) (n=31)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interval between radiation and surgery (days) (mean, SD) (excluding durvalumab)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.8 (24) (n=25)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interval between radiation and surgery (days) (mean, SD) (only durvalumab)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">163 (44) (n=6)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><p>Driver mutation group includes mutations in EGFR, RET, ROS and BRAF. GTV: gross tumor volume of the primary lesion, Lung V20: percent of lung receiving 20 Gray, Lung V5: percent of the lung receiving 5 Gray, Heart V45: percent of the heart receiving 45 Gray, PTV D95% the volume of the planning target volume receiving 95% of the dose. Programmed death-ligand one (PD-L1) Immunohistochemistry (IHC)</p></fn></table-wrap-foot></table-wrap><p>Comparison between the groups showed that the driver mutation group consisted of adenocarcinomas, mostly never smokers, had smaller GTVs (<italic toggle="yes">p</italic> = 0.047), smaller total tumor volumes (<italic toggle="yes">p</italic> = 0.016), and did not receive durvalumab post-ChRT (<italic toggle="yes">p</italic> = 0.08).</p><p>The no-driver mutation group had both adeno- and squamous cell carcinomas, were primarily smokers, had larger GTVs, larger total tumor volumes, and included a few patients (<italic toggle="yes">n</italic> = 6) who received durvalumab prior to undergoing completion surgery. The time interval between the end of NA-ChRT and surgery was longer for the six cases treated with durvalumab prior to surgery (mean 163 days, SD 44) than cases in the no-driver mutation group that did not receive durvalumab (mean 61.8 days, SD 24), or the driver mutation group (mean 56 days, SD 20, <italic toggle="yes">p</italic> = 0.002) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>
<xref rid="T2" ref-type="table">Table 2A</xref> presents each identified biomarker and its response to therapy measured by MPR, pCR, and MRTC in the surgical specimens following NA-ChRT. The driver mutation group demonstrated low pCR, MPR, and high MRTC. The MRTC for this group was 43.4% for EGFR (<italic toggle="yes">n</italic> = 13), 50% for RET (<italic toggle="yes">n</italic> = 1), 50% for ROS1 (50%, <italic toggle="yes">n</italic> = 1), and 45% for BRAF (<italic toggle="yes">n</italic> = 1). Mutations represented by only a solitary case each (RET/ROS1/BRAF) were excluded from the driver mutation group for the UVA and MVA, leaving an EGFR-only group (<italic toggle="yes">n</italic> = 13) for analysis.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Pathologic response to chemo-radiation according to EGFR mutation</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Grouping</bold>
</td><td align="center" valign="bottom" colspan="2" rowspan="1">
<bold>The leading mutation</bold>
</td><td align="center" valign="bottom" colspan="3" rowspan="1">
<bold>MPR</bold>
</td><td align="center" valign="bottom" colspan="3" rowspan="1">
<bold>pCR</bold>
</td><td align="center" valign="bottom" colspan="2" rowspan="1">
<bold>Mean residual tumor cells (%)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">Driver mutations</td><td align="center" valign="top" colspan="2" rowspan="1">EGFR <italic toggle="yes">N</italic> = 13</td><td align="center" valign="top" colspan="3" rowspan="1">3/13 (23%)</td><td align="center" valign="top" colspan="3" rowspan="1">0/13 (0%)</td><td align="center" valign="top" colspan="2" rowspan="1">43.4% (SD35)</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">BRAF <italic toggle="yes">N</italic> = 1</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (0%)</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (0%)</td><td align="center" valign="top" colspan="2" rowspan="1">45%</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">RET <italic toggle="yes">N</italic> = 1</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (0%)</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (0%)</td><td align="center" valign="top" colspan="2" rowspan="1">50%</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">ROS <italic toggle="yes">N</italic> = 1</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (0%)</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (0%)</td><td align="center" valign="top" colspan="2" rowspan="1">50%</td></tr><tr><td align="left" valign="top" rowspan="5" colspan="1">No driver mutations</td><td align="center" valign="top" colspan="2" rowspan="1">FGFR <italic toggle="yes">N</italic> = 2</td><td align="center" valign="top" colspan="3" rowspan="1">2/2 (100%)</td><td align="center" valign="top" colspan="3" rowspan="1">2/2 (100%)</td><td align="center" valign="top" colspan="2" rowspan="1">0% (SD 0)</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">KRAS <italic toggle="yes">N</italic> = 10</td><td align="center" valign="top" colspan="3" rowspan="1">8/10 (80%)</td><td align="center" valign="top" colspan="3" rowspan="1">4/10 (40%)</td><td align="center" valign="top" colspan="2" rowspan="1">13.7% (SD 23)</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">ERBB4 <italic toggle="yes">N</italic> = 1</td><td align="center" valign="top" colspan="3" rowspan="1">1/1 (100%)</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (100%)</td><td align="center" valign="top" colspan="2" rowspan="1">5%</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">AKT amplification <italic toggle="yes">N</italic> = 1</td><td align="center" valign="top" colspan="3" rowspan="1">1/1 (100%)</td><td align="center" valign="top" colspan="3" rowspan="1">0/1 (100%)</td><td align="center" valign="top" colspan="2" rowspan="1">9%</td></tr><tr><td align="center" valign="top" colspan="2" rowspan="1">Negative for mutation <italic toggle="yes">N</italic> = 17</td><td align="center" valign="top" colspan="3" rowspan="1">11/17 (64.7%)</td><td align="center" valign="top" colspan="3" rowspan="1">3/17 (17.6%)</td><td align="center" valign="top" colspan="2" rowspan="1">19.9% (SD24)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">
<bold>Biomarker grouping</bold>
</td><td align="left" valign="top" colspan="2" rowspan="1">
<bold>MPR (n, %)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>p</bold>
</italic>
<bold>-value</bold>
</td><td align="left" valign="top" colspan="2" rowspan="1">
<bold>pCR (n, %)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>p</bold>
</italic>
<bold>-value</bold>
</td><td align="left" valign="top" colspan="2" rowspan="1">
<bold>MRTC (%, SD)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>p</bold>
</italic>
<bold>-value</bold>
</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Driver mutations N = 16</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">3/16 (19%)</td><td align="char" valign="top" char="decimal" rowspan="1" colspan="1">0.0001</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">0/16 (0%)</td><td align="char" valign="top" char="decimal" rowspan="1" colspan="1">0.004</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">44.4% (SD 31)</td><td align="char" valign="top" char="decimal" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">EGFR only mutations <italic toggle="yes">N</italic> = 13</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">3/13 (23%)</td><td align="char" valign="top" char="decimal" rowspan="1" colspan="1">0.003</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">0/13 (0%)</td><td align="char" valign="top" char="decimal" rowspan="1" colspan="1">0.02</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">43.4% (SD 35)</td><td align="char" valign="top" char="decimal" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">No driver mutations <italic toggle="yes">N</italic> = 31</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">22/31 (71%)</td><td align="left" valign="top" rowspan="1" colspan="1">reference</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">8/31 (26%)</td><td align="left" valign="top" rowspan="1" colspan="1">reference</td><td align="char" valign="top" colspan="2" char="decimal" rowspan="1">15.8% (SD 22.4)</td><td align="left" valign="top" rowspan="1" colspan="1">reference</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><p>Abbreviations: Epidermal growth factor receptor (EGFR), Major pathologic response (MPR), Mean residual tumor cells (MRTC) Pathologic complete response (pCR). The driver mutations group include EGFR, RET, ROS1 and BRAF. The EGFR only group excluded RET, ROS and BRAF from the analysis. P values are for comparison of no- driver mutations to driver mutations and EGFR only mutations.</p></fn></table-wrap-foot></table-wrap><p>Mutations within the no-driver mutation group had higher rates of pCR, MPR, and lower MRTC. This group had low MRTC: 13.7% for KRAS (<italic toggle="yes">n</italic> = 10), 5% for ERBB4 (<italic toggle="yes">n</italic> = 1), 9% for AKT (<italic toggle="yes">n</italic> = 1), 0% for FGFR (<italic toggle="yes">n</italic> = 2), and 19.9% for patients who had no mutations identified (<italic toggle="yes">n</italic> = 17) on molecular testing. The no-driver mutation group was unchanged for the UVA and MVA. The no-driver mutation group was composed chiefly of cases with either KRAS mutation (<italic toggle="yes">n</italic> = 10) or no identifiable mutation (<italic toggle="yes">n</italic> = 17). These two subgroups of the no-driver-mutation group showed similar rates of pCR, MPR, and MRTC. Furthermore, Kaplan&#8211;Meier estimates of local control, DFS, and OS at 2 years for KRAS mutations and no-mutations showed no significant differences between cases with KRAS or no mutations identified (<xref rid="suppl1" ref-type="supplementary-material">Figure S1 A&#8211;C</xref>). For KRAS <italic toggle="yes">vs.</italic> no mutations identified, LC at 2 years was 80% (95% CI 40&#8211;95) <italic toggle="yes">vs.</italic> 89% (95% CI 62&#8211;97) (<italic toggle="yes">p</italic> = 0.2), DFS was 60% (95% CI 25&#8211;83%) <italic toggle="yes">vs.</italic> 41% (95% CI 20&#8211;63%) (<italic toggle="yes">p</italic> = 0.7), and OS trended lower for KRAS: 70% (95% CI 33&#8211;89) <italic toggle="yes">vs.</italic> 90.5% (95% CI 67&#8211;97) (<italic toggle="yes">p</italic> = 0.18).</p><supplementary-material id="suppl1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Figure 1.</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjr.20220763.suppl-01.pptx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><p>Comparison between the EGFR-only and no-driver mutation groups (<xref rid="T2" ref-type="table">Table 2B</xref>) showed the EGFR group had higher rates of MRTC (43.4% <italic toggle="yes">vs.</italic> 15.8%, <italic toggle="yes">p</italic> = 0.009) and lower rates of MPR (23% <italic toggle="yes">vs.</italic> 71%, <italic toggle="yes">p</italic> = 0.003) and pCR (0% <italic toggle="yes">vs.</italic> 26%, <italic toggle="yes">p</italic> = 0.02).</p><p>The UVA (<xref rid="T3" ref-type="table">Table 3</xref>) showed that the likelihood of MPR was increased for smokers (OR 0.34, <italic toggle="yes">p</italic> = 0.005), squamous cell histology (OR 0.53, <italic toggle="yes">p</italic> = 0.063), NA-ChRT surgery interval &gt;65 days (OR 0.12, <italic toggle="yes">p</italic> = 0.005), and absence of an EGFR mutation (OR 0.35, <italic toggle="yes">p</italic> = 0.006). Cases receiving durvalumab before surgery trended towards a higher rate of MPR (83% <italic toggle="yes">vs</italic> 53%, OR 0.45, <italic toggle="yes">p</italic> = 0.16). PD-L1 status did not influence MPR.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>Uni- and multivariate analysis predicting the odds ratio for MPR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="2" colspan="1">MPR N/TOTAL (%)</th><th align="center" valign="bottom" colspan="2" rowspan="1">UVA</th><th align="center" valign="bottom" colspan="2" rowspan="1">MVA</th></tr><tr><th align="center" valign="bottom" rowspan="1" colspan="1">Odds ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>- value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Odds ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>- value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.95-1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.78</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.5 (0.17-1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Female n=18</td><td align="center" valign="top" rowspan="1" colspan="1">8/18 (44%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Male n=29</td><td align="center" valign="top" rowspan="1" colspan="1">17/29 (58%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking<sup>a</sup>:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.34 (0.16-0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Never n=15</td><td align="center" valign="top" rowspan="1" colspan="1">3/15 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Past n=5</td><td align="center" valign="top" rowspan="1" colspan="1">3/5 (60%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Current N=27</td><td align="center" valign="top" rowspan="1" colspan="1">19/27 (70%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Histology<sup>a</sup>:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.3-1.01)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Squamous n=5</td><td align="center" valign="top" rowspan="1" colspan="1">5/5 (100%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Adenocarcinoma n=35</td><td align="center" valign="top" rowspan="1" colspan="1">16/35 (46%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Other histology n=7</td><td align="center" valign="top" rowspan="1" colspan="1">4/7 (57%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stage:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.3 (0.07-2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;II n=5</td><td align="center" valign="top" rowspan="1" colspan="1">2/5 (40%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;III n=40</td><td align="center" valign="top" rowspan="1" colspan="1">22/41 (53%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;IV n=1</td><td align="center" valign="top" rowspan="1" colspan="1">1/1 (100%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor volume:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.16-1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8804;115cc n=25</td><td align="center" valign="top" rowspan="1" colspan="1">12/25 (48%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&gt;115cc n=21</td><td align="center" valign="top" rowspan="1" colspan="1">13/21 (62%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Location of primary tumor:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.5 (0.6-9.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">1.7 (0.4-7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Upper lobe n=34</td><td align="center" valign="top" rowspan="1" colspan="1">16/34 (48%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Lower lobe n=13</td><td align="center" valign="top" rowspan="1" colspan="1">9/13 (69%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemotherapy:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cisplatin-vinorelbine</td><td align="center" valign="top" rowspan="1" colspan="1">4/10 (40%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.98 (0.63-1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.92</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Carboplatin-paclitaxel Q1W</td><td align="center" valign="top" rowspan="1" colspan="1">13/24 (54%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Carboplatin-paclitaxel Q3W</td><td align="center" valign="top" rowspan="1" colspan="1">2/2 (100%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cisplatin-etoposide</td><td align="center" valign="top" rowspan="1" colspan="1">6/7 (86%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cisplatin-pemetrexed</td><td align="center" valign="top" rowspan="1" colspan="1">0/3 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Durvalumab:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.15-1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.7 (0.2-2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;No n=41</td><td align="center" valign="top" rowspan="1" colspan="1">20/41 (49%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yes n=6</td><td align="center" valign="top" rowspan="1" colspan="1">5/6 (83%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiation dose:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.3-3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8804;55 Gy n=32</td><td align="center" valign="top" rowspan="1" colspan="1">17/32 (53%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&gt;56 Gy n=15</td><td align="center" valign="top" rowspan="1" colspan="1">8/15 (53%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiation technique:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.8 (0.25-2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;3DCT n=20</td><td align="center" valign="top" rowspan="1" colspan="1">10/20 (50%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;VMAT n=27</td><td align="center" valign="top" rowspan="1" colspan="1">15/27 (56%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Breathing management:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.66 (0. 3-1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;DIBH n=8</td><td align="center" valign="top" rowspan="1" colspan="1">3/8 (37%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;FB n=38</td><td align="center" valign="top" rowspan="1" colspan="1">22/38 (58%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adaptive planning due to tumor shrinkage:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.9 (0.7-12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">1.6 (0.37-6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yes n=10</td><td align="center" valign="top" rowspan="1" colspan="1">7/10 (70%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;No n=36</td><td align="center" valign="top" rowspan="1" colspan="1">17/36 (47%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;No-EGFR n=31</td><td align="center" valign="top" rowspan="1" colspan="1">22/31 (71%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35 (0.16-0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.18-0.86)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;EGFR n=13</td><td align="center" valign="top" rowspan="1" colspan="1">3/13 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PDL1 status<sup>b</sup>:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (0.43-2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Negative n=11</td><td align="center" valign="top" rowspan="1" colspan="1">6/11 (54%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weak positive n=11</td><td align="center" valign="top" rowspan="1" colspan="1">5/11 (45%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Strong positive n=11</td><td align="center" valign="top" rowspan="1" colspan="1">6/11 (54%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time interval radiation to surgery<sup>a</sup>:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.02-0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8804;65 days n=30</td><td align="center" valign="top" rowspan="1" colspan="1">11/30 (36.7%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&gt;65 days n=17</td><td align="center" valign="top" rowspan="1" colspan="1">14/17 (82%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><p>Major pathologic regression (MPR), Gray (Gy), Three-dimensional conformal radiation therapy (3DCRT), Volumetric arc therapy (VMAT), Deep inspiratory breath hold (DIBH), Free breathing (FB), Epidermal growth factor receptor (EGFR), Chemoradiation (ChRT).</p></fn><fn id="T3_FN2"><label>a</label><p>Smoking, histology, and time interval between ChRT and surgery correlated with EGFR mutation (smoking <italic toggle="yes">p</italic> &lt; 0.0001, histology <italic toggle="yes">p</italic> = 0.013, time interval between ChRT and surgery <italic toggle="yes">p</italic> = 0.048). Thus, they were excluded from the MVA.</p></fn><fn id="T3_FN3"><label>b</label><p>PDL1 status negative (&lt; 1% positive staining); weak positive (1&#8211;49%) and strong positive (&#8805; 50%).</p></fn></table-wrap-foot></table-wrap><p>We excluded from the MVA the co-variables that correlated significantly with EGFR: never-smoking (<italic toggle="yes">p</italic> &lt; 0.0001), adenocarcinoma histology (<italic toggle="yes">p</italic> = 0.013), and the time interval between radiation and surgery (<italic toggle="yes">p</italic> = 0.048). Only the no-driver mutation group (OR 0.39, <italic toggle="yes">p</italic> = 0.02) remained significant for tumor regression on MVA.</p><p>
<xref rid="F2" ref-type="fig">Figure 2</xref> compares local control, DFS, and OS at 2 years for the EGFR and no-driver mutation groups. 2-year DFS was lower for the EGFR group: 8% (95% CI 1&#8211;29%) <italic toggle="yes">vs.</italic> 45% (95% CI 29&#8211;65%), HR 0.5, <italic toggle="yes">p</italic> = 0.001. Local control trended lower for the EGFR group: 52% (95% CI 20&#8211;76%) <italic toggle="yes">vs.</italic> 85.8% (95% CI 66.5&#8211;95%), HR 0.67, <italic toggle="yes">p</italic> = 0.17. OS was not significantly different for the EGFR group: 69.2% (95% CI 37&#8211;87%) <italic toggle="yes">vs.</italic> 84% (95% CI 65&#8211;93%), HR 1.04, <italic toggle="yes">p</italic> = 0.86.</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>(a<bold>&#8211;</bold>c): Kaplan Meier estimated of (a) local control, (b) disease free survival and (c) overall survival for driver mutation (N=16) vs. no driver mutation (N=31).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bjr.20220763.g002.jpg"/></fig><p>We knew PD-L1 receptor status in 37 cases. <xref rid="T4" ref-type="table">Table 4</xref> presents the rates of MPR and pCR and the MRTC between negative, weakly positive, and strongly positive PD-L1 staining. There were no differences in MPR, pCR, or MRTC between the PD-L1 negative, weakly positive or strongly positive subgroups. <xref rid="suppl2" ref-type="supplementary-material">Figure S2</xref> presents a scatterplot showing MRTC according to the percent of PD-L1 staining, showing no correlation between the percentage of MRTC and the percentage of the PD-L1 positivity (<italic toggle="yes">p</italic> = 0.5).</p><supplementary-material id="suppl2" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Figure 2.</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjr.20220763.suppl-02.pptx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4.</label><caption><p>Pathologic response to chemoradiation according to and PDL-1 staining</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">PDL-1 staining</th><th align="center" valign="bottom" rowspan="1" colspan="1">MPR (n, %)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">pCR (n, %)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">MRTC (%, SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Negative (<italic toggle="yes">N</italic> = 13)</td><td align="center" valign="top" rowspan="1" colspan="1">7/13 (54%)</td><td align="center" valign="top" rowspan="3" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">1/13 (7.7%)</td><td align="center" valign="top" rowspan="3" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">22 (7.2)</td><td align="center" valign="top" rowspan="3" colspan="1">0.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weak positive (<italic toggle="yes">N</italic> = 13)</td><td align="center" valign="top" rowspan="1" colspan="1">6/13 (46%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/13 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (7.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Strong positive (<italic toggle="yes">N</italic> = 11)</td><td align="center" valign="top" rowspan="1" colspan="1">6/11 (54.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/11 (27%)</td><td align="center" valign="top" rowspan="1" colspan="1">17.3 (7.8)</td></tr></tbody></table><table-wrap-foot><fn id="T4_FN1"><p>Abbreviations: Major pathologic response (MPR), Mean residual tumor cells (MRTC), Pathologic complete response (pCR). PDL-1 negative &lt;1% staining; weak positive 1-49% and strong positive &#8805;50%.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>To the best of our knowledge, this is the first study in patients with LA-NSCLC describing pathologic regression as a function of EGFR mutation in surgical specimens following aggressive NA-ChRT using a radiation dose in the neoadjuvant setting similar to the doses used when delivering definitive treatment. We used three pathologic end points; the rate of MPR, the rate of pCR, and the percentage of MRTC to measure response to NA-ChRT. Comparison between the EGFR and the no-driver mutation groups showed lower rates of MPR (23% <italic toggle="yes">vs.</italic> 71%, <italic toggle="yes">p</italic> = 0.003) and pCR (0% <italic toggle="yes">vs.</italic> 26%, <italic toggle="yes">p</italic> = 0.02) and higher MRTC (43.4% <italic toggle="yes">vs.</italic> 15.8%, <italic toggle="yes">p</italic> = 0.009) in the EGFR mutation group. These three parameters all point to the same conclusion, the pathologic regression rates in surgical specimens following NA-ChRT were reduced if an EGFR mutation was present in the tumor.</p><p>In contrast to the poor outcomes reported in the EGFR mutation group, the pCR rate of 26% in our no-driver group was consistent with the rate of pCR reported in several large retrospective trials evaluating pathologic response following NA-ChRT in resectable LA-NSCLC. Lococo et al reported a pCR in 22% of cases in a study of 279 patients with LA-NSCLC treated with NA-ChRT,<sup>
<xref rid="b30" ref-type="bibr">30</xref>
</sup> and Haque et al, in a large database study, reported the rate of pCR was 17%<sup>
<xref rid="b31" ref-type="bibr">31</xref>
</sup> following NA-ChRT. In contrast to these findings, in our study, the rate of pCR in the EGFR group was 0% following an aggressive course of NA-ChRT that used higher RT doses than those used in these studies.</p><p>In addition to the poor response in surgical specimens, the DFS of patients with an EGFR mutation was also reduced compared to patients with no-driver mutations (HR 0.5 <italic toggle="yes">p</italic> = 0.001, <xref rid="F2" ref-type="fig">Figure 2</xref>). Since the NA-ChRT protocol at our institution uses radiation doses commonly used when delivering definitive ChRT without resection, the low rates of pathologic regression and the short duration of DFS in patients with EGFR mutations observed in our study resonates with the poor results observed in patients with EGFR mutations treated with definitive ChRT. A recent study by Butkiewicz et al analyzed the outcome of 205 NSCLC patients treated with definitive platinum-based ChRT as a function of EGFR polymorphism (SNPs). They showed that patients with inoperable disease and functional EGFR genetic variants had poor clinical outcomes. They suggested that EGFR variants associated with elevated gene expression and protein activity may predict the decreased therapeutic efficacy of ChRT and that the EGFR SNPs may act as independent molecular prognostic predictors.<sup>
<xref rid="b32" ref-type="bibr">32</xref>
</sup> Akimoto et al showed that the levels of EGFR expression correlated inversely with radiation-induced apoptosis, suggesting that lack of sensitivity to apoptosis induction may be an important mechanism responsible for the radioresistance of tumors with high EGFR expression.<sup>
<xref rid="b33" ref-type="bibr">33</xref>
</sup> Chen et al described the role of EGFR in the repair of radiation-induced DNA damage. They suggested that EGFR confers tumor radiation resistance by activating survival and cell proliferation pathways.<sup>
<xref rid="b34" ref-type="bibr">34</xref>
</sup> Further studies are required to gain insight into the role of EGFR and other driver mutations in RT-induced cancer cell death.</p><p>We found that adenocarcinoma and never-smoking status correlated with reduced tumor regression. These variables are known to be associated with EGFR mutations.<sup>
<xref rid="b35" ref-type="bibr">35,36</xref>
</sup> Kayawake et al evaluated the response to ChRT in patients with NSCLC. They showed that patients with adenocarcinoma responded less to ChRT and that only squamous cell carcinoma was associated with achieving a pCR (<italic toggle="yes">p</italic> = 0.009).<sup>
<xref rid="b3" ref-type="bibr">3</xref>
</sup> One of the differences between squamous cell and adenocarcinoma is that the latter is more likely to harbor a driver mutation such as EGFR, ALK, RET, or ROS1 which may explain the findings in Kayawake&#8217;s study.<sup>
<xref rid="b37" ref-type="bibr">37</xref>
</sup>
</p><p>PD-L1 status did not correlate with pathologic regression measured by MPR, pCR, and MRTC. This finding contrasts with using the PD-L1 biomarker to predict response to immune checkpoint inhibitors in patients with metastatic disease.<sup>
<xref rid="b37" ref-type="bibr">37,38</xref>
</sup> Combining treatment with an immune checkpoint inhibitor and radiation is under investigation and may improve response.<sup>
<xref rid="b39" ref-type="bibr">39</xref>
</sup> Although durvalumab was used sparingly in this cohort, with only 6 of 31 patients in the no-driver mutation group receiving any durvalumab therapy, cases receiving durvalumab prior to surgery trended towards a higher chance for MPR (83% <italic toggle="yes">vs.</italic> 53%, OR 0.45, <italic toggle="yes">p</italic> = 0.16).</p><p>Patients with a KRAS mutation had more tumor regression in surgical specimens following ChRT and longer DFS following surgery than patients with an EGFR mutation, yet, trended towards a shorter duration of OS (<xref rid="suppl1" ref-type="supplementary-material">Figure S1C</xref>). We suggest interpreting this finding cautiously due to the small number of patients in our study with KRAS mutations (<italic toggle="yes">n</italic> = 10). The discrepancy between the favorable rates of pathologic regression observed in our study and the poor prognosis reported for patients with KRAS mutations<sup>
<xref rid="b29" ref-type="bibr">29,40</xref>
</sup> deserves further investigation. Enhancing treatment with immunotherapy or downstream inhibitors such as RAF or MEK inhibitors<sup>
<xref rid="b41" ref-type="bibr">41</xref>
</sup> may improve clinical outcomes for these patients.</p><p>Potential bias in our data may result from selecting a single genetic alteration for analysis without accounting for other mutations that may co-exist and cause undetected interactions. This cohort included several genetic alterations. The rare mutations RET, ROS1, and BRAF were excluded from the EGFR group to produce a homogenous group for UVA and MVA regression analysis. We plan to investigate these rare mutations further in a larger cohort. Also, we had no cases of ALK rearrangement or MET mutation. Although the number of cases in the EGFR and no-driver mutation groups was small, the differences in pathologic response observed between the groups were sufficiently large to be significant. Other biases may result from using durvalumab in six patients within the no-driver mutation group. The improved outcomes with the use of neoadjuvant immunotherapy with chemotherapy compared to chemotherapy alone in patients with Stage IB-IIIA NSCLC reported recently in the Checkmate 816 trial<sup>
<xref rid="b42" ref-type="bibr">42</xref>
</sup> suggests that the use of neoadjuvant durvalumab in six patients in the no-driver mutation group may have contributed to the better rates of pathologic regression and longer DFS observed in these patients. However, the proportion of patients who received durvalumab was small and unlikely to have impacted the results of MVA.</p><p>TKIs prolong survival significantly in patients with metastatic disease and EGFR-mutated tumors.<sup>
<xref rid="b43" ref-type="bibr">43</xref>
</sup> Tyrosine kinase inhibitors were used in our cohort for recurrent disease, thus, explaining the discrepancy between shorter DFS yet similar OS between the driver mutation and the no-driver mutation groups (<xref rid="F2" ref-type="fig">Figure 2</xref>). Since patients received TKIs only after surgery, their use did not affect the rates of pathologic regression observed in the surgical specimens.</p><p>For Stage IB-III NSCLC resectable EGFR mutated tumors, the ADUARA trial has shown that adjuvant osimertinib significantly prolonged DFS compared with placebo.<sup>
<xref rid="b12" ref-type="bibr">12</xref>
</sup> Treatment with osimertinib has rapidly become the standard of care in these clinical settings. Current studies such as the NEOADAURA trial, which evaluates the use of neoadjuvant osimertinib in patients with resectable NSCLC prior to surgery,<sup>
<xref rid="b13" ref-type="bibr">13</xref>
</sup> and the LAURA trial, which is investigating the use of adjuvant osimertinib following ChRT in patients with unresectable LA-NSCLC,<sup>
<xref rid="b14" ref-type="bibr">14</xref>
</sup> may further improve outcomes in patients with EGFR mutated tumors treated with ChRT. Current guidelines for patients with unresectable NSCLC suggest treating patients with definitive ChRT and consolidation durvalumab regardless of driver mutation.<sup>
<xref rid="b44" ref-type="bibr">44</xref>
</sup> As a result, deferring or not conducting molecular testing reduces the opportunity for patients to participate in clinical trials and potentially derive benefit from early treatment with targeted therapies such as osimertinib.<sup>
<xref rid="b4" ref-type="bibr">4,5</xref>
</sup> Given the poor pathologic regression and short duration of DFS in the EGFR cohort detected in our study, we recommend that patients with LA-NSCLC undergo molecular testing for driver mutations allowing for targeted therapies to be introduced earlier in their course of treatment via clinical trials.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>Patients with resectable LA-NSCLC and a driver mutation had poor tumor regression in pathology specimens and shorter DFS following NA-ChRT and surgery. PD-L1 was not associated with tumor regression. Future studies in patients with LA-NSCLC should include molecular testing for tumor driver mutations for prognostication and treatment decisions.</p></sec></body><back><fn-group><fn fn-type="ethics"><p><bold>Ethics approval:</bold> This study was approved by the institutional review board for retrospective analysis (approval number SMC-2678-15).</p></fn><fn fn-type="equal" id="equal-contrib1"><p>The authors Sarit Appel, Akram Saad, Jair Bar and Jeffrey Goldstein contributed equally to the work.</p></fn><fn fn-type="disclosure"><p><bold>Prior presentations:</bold> Presented in part at the annual meeting of ESTRO 2021, Madrid, Spain.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sequist</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>JC-H</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>N</given-names></name>, <name name-style="western"><surname>O&#8217;Byrne</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hirsh</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Mok</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>. <article-title>Phase III study of Afatinib or cisplatin plus Pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations</article-title>. <source>J Clin Oncol</source><year>2013</year>; <volume>31</volume>: <fpage>3327</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2012.44.2806</pub-id><pub-id pub-id-type="pmid">23816960</pub-id></mixed-citation></ref><ref id="b2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y-L</given-names></name>, <name name-style="western"><surname>Thongprasert</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C-H</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>D-T</given-names></name>, <name name-style="western"><surname>Saijo</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>. <article-title>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</article-title>. <source>N Engl J Med</source><year>2009</year>; <volume>361</volume>: <fpage>947</fpage>&#8211;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa0810699</pub-id><pub-id pub-id-type="pmid">19692680</pub-id></mixed-citation></ref><ref id="b3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayawake</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Okumura</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yamanashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Takahashi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Itasaka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yoshioka</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>. <article-title>Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes</article-title>. <source>Gen Thorac Cardiovasc Surg</source><year>2019</year>; <volume>67</volume>: <fpage>773</fpage>&#8211;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11748-019-01076-9</pub-id><pub-id pub-id-type="pmid">30725275</pub-id></mixed-citation></ref><ref id="b4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gross</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Ogale</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kent</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>WB</given-names></name></person-group>. <article-title>Associations between Medicaid insurance, biomarker testing, and outcomes in patients with advanced NSCLC</article-title>. <source>J Natl Compr Canc Netw</source><year>2022</year>; <volume>20</volume>: <fpage>479</fpage>&#8211;<lpage>487</lpage>. doi: <pub-id pub-id-type="doi">10.6004/jnccn.2021.7083</pub-id><pub-id pub-id-type="pmid">35545174</pub-id></mixed-citation></ref><ref id="b5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Kesselheim</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Avorn</surname><given-names>J</given-names></name></person-group>. <article-title>Variation in use of lung cancer targeted therapies across state Medicaid programs, 2020-2021</article-title>. <source>JAMA Netw Open</source><year>2023</year>; <volume>6</volume>(): <elocation-id>e2252562</elocation-id>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.52562</pub-id><pub-id pub-id-type="pmid">36696113</pub-id><pub-id pub-id-type="pmcid">PMC10187487</pub-id></mixed-citation></ref><ref id="b6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faivre-Finn</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vicente</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kurata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Planchard</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Paz-Ares</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Vansteenkiste</surname><given-names>JF</given-names></name>, <etal>et al</etal></person-group>. <article-title>Four-year survival with Durvalumab after Chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial</article-title>. <source>J Thorac Oncol</source><year>2021</year>; <volume>16</volume>: <fpage>860</fpage>&#8211;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jtho.2020.12.015</pub-id><pub-id pub-id-type="pmid">33476803</pub-id></mixed-citation></ref><ref id="b7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonia</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Villegas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Daniel</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Vicente</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Murakami</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>. <article-title>Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><year>2017</year>; <volume>377</volume>: <fpage>1919</fpage>&#8211;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1709937</pub-id><pub-id pub-id-type="pmid">28885881</pub-id></mixed-citation></ref><ref id="b8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Komaki</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Masters</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Blumenschein</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Schild</surname><given-names>SE</given-names></name>, <etal>et al</etal></person-group>. <article-title>Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose Chemoradiotherapy with or without Cetuximab for Unresectable stage III non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source><year>2020</year>; <volume>38</volume>: <fpage>706</fpage>&#8211;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.19.01162</pub-id><pub-id pub-id-type="pmid">31841363</pub-id><pub-id pub-id-type="pmcid">PMC7048161</pub-id></mixed-citation></ref><ref id="b9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>. <article-title>A multicenter retrospective study on the prognosis of stage III Unresectable mutant non-small cell lung cancer with tyrosine kinase inhibitors therapy</article-title>. <source>Front Oncol</source><year>2021</year>; <volume>11</volume>: <elocation-id>692703</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2021.692703</pub-id><pub-id pub-id-type="pmid">34322390</pub-id><pub-id pub-id-type="pmcid">PMC8311792</pub-id></mixed-citation></ref><ref id="b10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ready</surname><given-names>N</given-names></name>, <name name-style="western"><surname>J&#228;nne</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Bogart</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dipetrillo</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Garst</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Graziano</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>. <article-title>Chemoradiotherapy and Gefitinib in stage III non-small cell lung cancer with Epidermal growth factor receptor and KRAS Mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial</article-title>. <source>J Thorac Oncol</source><year>2010</year>; <volume>5</volume>: <fpage>1382</fpage>&#8211;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181eba657</pub-id><pub-id pub-id-type="pmid">20686428</pub-id></mixed-citation></ref><ref id="b11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y-L</given-names></name>, <name name-style="western"><surname>Tsuboi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J</given-names></name>, <name name-style="western"><surname>John</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Grohe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Majem</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>. <article-title>Osimertinib in Resected EGFR-Mutated non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><year>2020</year>; <volume>383</volume>: <fpage>1711</fpage>&#8211;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2027071</pub-id><pub-id pub-id-type="pmid">32955177</pub-id></mixed-citation></ref><ref id="b12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y-L</given-names></name>, <name name-style="western"><surname>John</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Grohe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Majem</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>. <article-title>Adjuvant Osimertinib for Resected EGFR-Mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial</article-title>. <source>JCO</source><year>2023</year>; <volume>41</volume>: <fpage>1830</fpage>&#8211;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.22.02186</pub-id><pub-id pub-id-type="pmcid">PMC10082285</pub-id><pub-id pub-id-type="pmid">36720083</pub-id></mixed-citation></ref><ref id="b13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuboi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Weder</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Escriu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Blakely</surname><given-names>C</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dacic</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>. <article-title>Neoadjuvant Osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-Mutated Resectable non-small-cell lung cancer: Neoadaura</article-title>. <source>Future Oncol</source><year>2021</year>; <volume>17</volume>: <fpage>4045</fpage>&#8211;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.2217/fon-2021-0549</pub-id><pub-id pub-id-type="pmid">34278827</pub-id><pub-id pub-id-type="pmcid">PMC8530153</pub-id></mixed-citation></ref><ref id="b14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Casarini</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cobo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>&#214;zg&#252;ro&#287;lu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hodge</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>. <article-title>Osimertinib maintenance after definitive Chemoradiation in patients with Unresectable EGFR Mutation positive stage III non-small-cell lung cancer: LAURA trial in progress</article-title>. <source>Clin Lung Cancer</source><year>2021</year>; <volume>22</volume>: <fpage>371</fpage>&#8211;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cllc.2020.11.004</pub-id><pub-id pub-id-type="pmid">33558193</pub-id></mixed-citation></ref><ref id="b15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zens</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bello</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Scherz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koenigsdorf</surname><given-names>J</given-names></name>, <name name-style="western"><surname>P&#246;llinger</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schmid</surname><given-names>RA</given-names></name>, <etal>et al</etal></person-group>. <article-title>A Prognostic score for non-small cell lung cancer Resected after Neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response</article-title>. <source>Mod Pathol</source><year>2021</year>; <volume>34</volume>: <fpage>1333</fpage>&#8211;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41379-021-00777-y</pub-id><pub-id pub-id-type="pmid">33714982</pub-id><pub-id pub-id-type="pmcid">PMC8216907</pub-id></mixed-citation></ref><ref id="b16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissferdt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pataer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vaporciyan</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Correa</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Sepesi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Moran</surname><given-names>CA</given-names></name>, <etal>et al</etal></person-group>. <article-title>Agreement on major pathological response in NSCLC patients receiving Neoadjuvant chemotherapy</article-title>. <source>Clin Lung Cancer</source><year>2020</year>; <volume>21</volume>: <fpage>341</fpage>&#8211;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cllc.2019.11.003</pub-id><pub-id pub-id-type="pmid">32279936</pub-id><pub-id pub-id-type="pmcid">PMC7305995</pub-id></mixed-citation></ref><ref id="b17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machtay</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Stevenson</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Shrager</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Algazy</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Treat</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>. <article-title>Two commonly used Neoadjuvant Chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response</article-title>. <source>J Thorac Cardiovasc Surg</source><year>2004</year>; <volume>127</volume>: <fpage>108</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jtcvs.2003.07.027</pub-id><pub-id pub-id-type="pmid">14752420</pub-id></mixed-citation></ref><ref id="b18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonett</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Suntharalingam</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Edelman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Gamliel</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Doyle</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>. <article-title>Pulmonary resection after curative intent radiotherapy (&gt;59 GY) and concurrent chemotherapy in non-small-cell lung cancer</article-title>. <source>Ann Thorac Surg</source><year>2004</year>; <volume>78</volume>: <fpage>1200</fpage>&#8211;<lpage>1205</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.athoracsur.2004.04.085</pub-id><pub-id pub-id-type="pmid">15464470</pub-id></mixed-citation></ref><ref id="b19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedel</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Budach</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Dippon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Spengler</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Eschmann</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Pfannenberg</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>. <article-title>Phase II trial of a Trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent Hyperfractionated Chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study</article-title>. <source>J Clin Oncol</source><year>2010</year>; <volume>28</volume>: <fpage>942</fpage>&#8211;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2008.21.7810</pub-id><pub-id pub-id-type="pmid">20100967</pub-id></mixed-citation></ref><ref id="b20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellmann</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Chaft</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>William</surname><given-names>WN</given-names></name>, <name name-style="western"><surname>Rusch</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Pisters</surname><given-names>KMW</given-names></name>, <name name-style="western"><surname>Kalhor</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>. <article-title>Pathological response after Neoadjuvant chemotherapy in Resectable non-small-cell lung cancers: proposal for the use of major pathological response as a Surrogate Endpoint</article-title>. <source>Lancet Oncol</source><year>2014</year>; <volume>15</volume>: <fpage>e42</fpage>&#8211;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(13)70334-6</pub-id><pub-id pub-id-type="pmid">24384493</pub-id><pub-id pub-id-type="pmcid">PMC4734624</pub-id></mixed-citation></ref><ref id="b21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junker</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Langner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klinke</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bosse</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name></person-group>. <article-title>Grading of tumor regression in non-small cell lung cancer: morphology and prognosis</article-title>. <source>Chest</source><year>2001</year>; <volume>120</volume>: <fpage>1584</fpage>&#8211;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1378/chest.120.5.1584</pub-id><pub-id pub-id-type="pmid">11713138</pub-id></mixed-citation></ref><ref id="b22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travis</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Dacic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wistuba</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sholl</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Adusumilli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bubendorf</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>. <article-title>IASLC Multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after Neoadjuvant therapy</article-title>. <source>J Thorac Oncol</source><year>2020</year>; <volume>15</volume>: <fpage>709</fpage>&#8211;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jtho.2020.01.005</pub-id><pub-id pub-id-type="pmid">32004713</pub-id><pub-id pub-id-type="pmcid">PMC8173999</pub-id></mixed-citation></ref><ref id="b23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirker</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Herth</surname><given-names>FJF</given-names></name>, <name name-style="western"><surname>Kerr</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Filipits</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Taron</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gandara</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>. <article-title>Consensus for EGFR Mutation testing in non-small cell lung cancer: results from a European workshop</article-title>. <source>J Thorac Oncol</source><year>2010</year>; <volume>5</volume>: <fpage>1706</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181f1c8de</pub-id><pub-id pub-id-type="pmid">20871269</pub-id></mixed-citation></ref><ref id="b24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>R. Wilcox</surname><given-names>W</given-names></name></person-group>. <article-title>Changing paradigm of cancer therapy: precision medicine by next-generation sequencing</article-title>. <source>Cancer Biol Med</source><year>2016</year>; <volume>13</volume>: <fpage>12</fpage>&#8211;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2016.0003</pub-id><pub-id pub-id-type="pmid">27144059</pub-id><pub-id pub-id-type="pmcid">PMC4850120</pub-id></mixed-citation></ref><ref id="b25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruglyak</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>FS</given-names></name></person-group>. <article-title>Next-generation sequencing and applications to the diagnosis and treatment of lung cancer</article-title>. <source>Adv Exp Med Biol</source><year>2016</year>; <volume>890</volume>: <fpage>123</fpage>&#8211;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-3-319-24932-2_7</pub-id><pub-id pub-id-type="pmid">26703802</pub-id></mixed-citation></ref><ref id="b26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Okamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Toyokawa</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kozuma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Matsubara</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Haratake</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>. <article-title>The expression of PD-L1 protein as a Prognostic factor in lung squamous cell carcinoma</article-title>. <source>Lung Cancer</source><year>2017</year>; <volume>104</volume>: <fpage>7</fpage>&#8211;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lungcan.2016.12.006</pub-id><pub-id pub-id-type="pmid">28213003</pub-id></mixed-citation></ref><ref id="b27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Goldstein</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Perelman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rabin</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Urban</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Onn</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>. <article-title>Neo-adjuvant Chemo-radiation to 60 gray followed by surgery for locally advanced non-small cell lung cancer patients: evaluation of Trimodality strategy</article-title>. <source>Isr Med Assoc J</source><year>2017</year>; <volume>19</volume>: <fpage>614</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">29103238</pub-id></mixed-citation></ref><ref id="b28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ben-Nun</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Perelman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Alezra</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Urban</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>. <article-title>Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional Conformal radiation in locally advanced lung cancer: pathological and clinical outcomes</article-title>. <source>Br J Radiol</source><year>2019</year>; <volume>92</volume>: <fpage>20180960</fpage>: <elocation-id>20180960</elocation-id>. doi: <pub-id pub-id-type="doi">10.1259/bjr.20180960</pub-id><pub-id pub-id-type="pmid">30864828</pub-id><pub-id pub-id-type="pmcid">PMC6580920</pub-id></mixed-citation></ref><ref id="b29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Osta</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Behera</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Sica</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pillai</surname><given-names>RN</given-names></name>, <etal>et al</etal></person-group>. <article-title>Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer Mutation consortium experience</article-title>. <source>J Thorac Oncol</source><year>2019</year>; <volume>14</volume>: <fpage>876</fpage>&#8211;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jtho.2019.01.020</pub-id><pub-id pub-id-type="pmid">30735816</pub-id><pub-id pub-id-type="pmcid">PMC8108452</pub-id></mixed-citation></ref><ref id="b30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lococo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sassorossi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nachira</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Chiappetta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Petracca Ciavarella</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Vita</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>. <article-title>Prognostic factors and long-term survival in locally advanced NSCLC with pathological complete response after surgical resection following Neoadjuvant therapy</article-title>. <source>Cancers (Basel)</source><year>2020</year>; <volume>12</volume>(): <elocation-id>3572</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/cancers12123572</pub-id><pub-id pub-id-type="pmid">33265905</pub-id><pub-id pub-id-type="pmcid">PMC7759985</pub-id></mixed-citation></ref><ref id="b31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Teh</surname><given-names>BS</given-names></name></person-group>. <article-title>Pathologic nodal clearance and complete response following Neoadjuvant Chemoradiation for clinical N2 non-small cell lung cancer: predictors and long-term outcomes</article-title>. <source>Lung Cancer</source><year>2019</year>; <volume>130</volume>: <fpage>93</fpage>&#8211;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lungcan.2019.02.003</pub-id><pub-id pub-id-type="pmid">30885358</pub-id></mixed-citation></ref><ref id="b32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butkiewicz</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Krze&#347;niak</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gdowicz-K&#322;osok</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Giglok</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marsza&#322;ek-Ze&#324;czak</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Suwi&#324;ski</surname><given-names>R</given-names></name></person-group>. <article-title>Polymorphisms in EGFR gene predict clinical outcome in Unresectable non-small cell lung cancer treated with radiotherapy and platinum-based Chemoradiotherapy</article-title>. <source>Int J Mol Sci</source><year>2021</year>; <volume>22</volume>(): <elocation-id>5605</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/ijms22115605</pub-id><pub-id pub-id-type="pmid">34070597</pub-id><pub-id pub-id-type="pmcid">PMC8197839</pub-id></mixed-citation></ref><ref id="b33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akimoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Buchmiller</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mason</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ang</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Milas</surname><given-names>L</given-names></name></person-group>. <article-title>Inverse relationship between Epidermal growth factor receptor expression and Radiocurability of murine Carcinomas</article-title>. <source>Clin Cancer Res</source><year>1999</year>; <volume>5</volume>: <fpage>2884</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">10537357</pub-id></mixed-citation></ref><ref id="b34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Nirodi</surname><given-names>CS</given-names></name></person-group>. <article-title>The Epidermal growth factor receptor: a role in repair of radiation-induced DNA damage</article-title>. <source>Clin Cancer Res</source><year>2007</year>; <volume>13</volume>: <fpage>6555</fpage>&#8211;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1610</pub-id><pub-id pub-id-type="pmid">18006754</pub-id></mixed-citation></ref><ref id="b35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vi&#241;olas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Garrido</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Isla</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Provencio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Majem</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Artal</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>. <article-title>Lung cancer in never-smoking women: A sub-analysis of the Spanish female-specific database World07</article-title>. <source>Cancer Invest</source><year>2017</year>; <volume>35</volume>: <fpage>358</fpage>&#8211;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.1080/07357907.2017.1295461</pub-id><pub-id pub-id-type="pmid">28350480</pub-id></mixed-citation></ref><ref id="b36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yano</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Haro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shikada</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Maruyama</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Maehara</surname><given-names>Y</given-names></name></person-group>. <article-title>&#8220;Non-small cell lung cancer in never Smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features&#8221;</article-title>. <source>Int J Clin Oncol</source><year>2011</year>; <volume>16</volume>: <fpage>287</fpage>&#8211;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10147-010-0160-8</pub-id><pub-id pub-id-type="pmid">21562939</pub-id></mixed-citation></ref><ref id="b37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Rangachari</surname><given-names>D</given-names></name></person-group>. <article-title>Management of advanced non-small cell lung cancers with known mutations or Rearrangements: latest evidence and treatment approaches</article-title>. <source>Ther Adv Respir Dis</source><year>2016</year>; <volume>10</volume>: <fpage>113</fpage>&#8211;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1753465815617871</pub-id><pub-id pub-id-type="pmid">26620497</pub-id><pub-id pub-id-type="pmcid">PMC5933559</pub-id></mixed-citation></ref><ref id="b38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name></person-group>. <article-title>Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials</article-title>. <source>Int Immunopharmacol</source><year>2020</year>; <volume>84</volume>: <fpage>106452</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106452</pub-id><pub-id pub-id-type="pmid">32339922</pub-id></mixed-citation></ref><ref id="b39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <etal>et al</etal></person-group>. <article-title>Safety and efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis</article-title>. <source>Cancer Med</source><year>2021</year>; <volume>10</volume>: <fpage>1222</fpage>&#8211;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cam4.3718</pub-id><pub-id pub-id-type="pmid">33465302</pub-id><pub-id pub-id-type="pmcid">PMC7926021</pub-id></mixed-citation></ref><ref id="b40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Zugazagoitia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Herbertz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>John</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Paz-Ares</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Schmid-Bindert</surname><given-names>G</given-names></name></person-group>. <article-title>KRAS-mutant non-small cell lung cancer: from biology to therapy</article-title>. <source>Lung Cancer</source><year>2018</year>; <volume>124</volume>: <fpage>53</fpage>&#8211;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lungcan.2018.07.013</pub-id><pub-id pub-id-type="pmid">30268480</pub-id></mixed-citation></ref><ref id="b41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uras</surname><given-names>IZ</given-names></name>, <name name-style="western"><surname>Moll</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Casanova</surname><given-names>E</given-names></name></person-group>. <article-title>Targeting KRAS mutant non-small-cell lung cancer: past, present and future</article-title>. <source>Int J Mol Sci</source><year>2020</year>; <volume>21</volume>(): <elocation-id>4325</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/ijms21124325</pub-id><pub-id pub-id-type="pmid">32560574</pub-id><pub-id pub-id-type="pmcid">PMC7352653</pub-id></mixed-citation></ref><ref id="b42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forde</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Spicer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Girard</surname><given-names>N</given-names></name></person-group>. <article-title>Neoadjuvant Nivolumab plus chemotherapy in Resectable lung cancer</article-title>. <source>N Engl J Med</source><year>2022</year>; <volume>387</volume>: <fpage>572</fpage>&#8211;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMc2208133</pub-id><pub-id pub-id-type="pmid">35947719</pub-id></mixed-citation></ref><ref id="b43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria</surname><given-names>J-C</given-names></name>, <name name-style="western"><surname>Ohe</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Vansteenkiste</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Reungwetwattana</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chewaskulyong</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name>, <etal>et al</etal></person-group>. <article-title>Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><year>2018</year>; <volume>378</volume>: <fpage>113</fpage>&#8211;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1713137</pub-id><pub-id pub-id-type="pmid">29151359</pub-id></mixed-citation></ref><ref id="b44"><label>44.</label><mixed-citation publication-type="webpage"><person-group><collab>National Comprehensive Cancer Network</collab></person-group>. <year>2023</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link></mixed-citation></ref></ref-list></back></article></pmc-articleset>